DE69935799D1 - Therapeutische zusammenstellungen - Google Patents

Therapeutische zusammenstellungen

Info

Publication number
DE69935799D1
DE69935799D1 DE69935799T DE69935799T DE69935799D1 DE 69935799 D1 DE69935799 D1 DE 69935799D1 DE 69935799 T DE69935799 T DE 69935799T DE 69935799 T DE69935799 T DE 69935799T DE 69935799 D1 DE69935799 D1 DE 69935799D1
Authority
DE
Germany
Prior art keywords
patient
physiologically acceptable
therapeutic compositions
acceptable ketosis
ketosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69935799T
Other languages
English (en)
Other versions
DE69935799T2 (de
Inventor
Richard L Veech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of DE69935799D1 publication Critical patent/DE69935799D1/de
Application granted granted Critical
Publication of DE69935799T2 publication Critical patent/DE69935799T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
DE69935799T 1998-09-15 1999-09-15 Therapeutische zusammenstellungen Expired - Lifetime DE69935799T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10037198P 1998-09-15 1998-09-15
US100371P 1998-09-15
PCT/US1999/021015 WO2000015216A1 (en) 1998-09-15 1999-09-15 Therapeutic compositions (ii)

Publications (2)

Publication Number Publication Date
DE69935799D1 true DE69935799D1 (de) 2007-05-24
DE69935799T2 DE69935799T2 (de) 2007-12-27

Family

ID=22279402

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69935799T Expired - Lifetime DE69935799T2 (de) 1998-09-15 1999-09-15 Therapeutische zusammenstellungen

Country Status (18)

Country Link
US (2) US20010014696A1 (de)
EP (1) EP1123094B1 (de)
JP (1) JP2002524506A (de)
KR (1) KR100805490B1 (de)
CN (1) CN1273129C (de)
AT (1) ATE359069T1 (de)
AU (1) AU767238B2 (de)
BR (1) BR9913680A (de)
CA (1) CA2339941A1 (de)
DE (1) DE69935799T2 (de)
DK (1) DK1123094T3 (de)
ES (1) ES2283133T3 (de)
HK (1) HK1035665A1 (de)
NZ (1) NZ509739A (de)
PT (1) PT1123094E (de)
RU (1) RU2242227C2 (de)
WO (1) WO2000015216A1 (de)
ZA (1) ZA200101260B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP1292294B1 (de) 2000-05-01 2009-03-18 Accera, Inc. Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
US20060280721A1 (en) 2003-06-03 2006-12-14 The Gov Of Usa Represented By Secretary Of Dpt Of Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
JP5114631B2 (ja) * 2003-09-01 2013-01-09 有限会社アーザス β−ヒドロキシ短〜中鎖脂肪酸重合体
US7132221B2 (en) * 2003-09-12 2006-11-07 Headway Technologies, Inc. Method to print photoresist lines with negative sidewalls
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
US7485743B2 (en) 2004-07-20 2009-02-03 Btg International Limited Oligomeric ketone compounds
ES2574557T3 (es) * 2004-09-21 2016-06-20 Btg International Limited Miméticos dopaminérgicos
GB0427145D0 (en) * 2004-12-10 2005-01-12 Ketocytonyx Inc Compositions for use in surgery
EP1915144A4 (de) 2005-06-20 2009-08-19 Accera Inc Verfahren zur reduzierung von oxidativen schäden und zur verbesserung der mitochondrien-effizienz
EP2001293B9 (de) 2006-04-03 2019-04-17 Accera, Inc. Verwendung ketogener verbindungen zur behandlung altersbedingter gedächtnisschwächen
US7807718B2 (en) * 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
WO2008120778A1 (ja) 2007-03-30 2008-10-09 Earthus, Inc. ケトン体生成促進剤組成物
BRPI0811052A2 (pt) * 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
CN101293831B (zh) * 2007-04-27 2013-09-18 汕头大学 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途
ES2556537T3 (es) * 2007-07-31 2016-01-18 Accera, Inc. Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
CN106038532B (zh) 2008-01-04 2019-05-14 牛津大学科技创新有限公司 用作降低血脂药剂的酮体和酮体酯
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CN106146591B (zh) * 2010-01-08 2020-07-31 Ionis制药公司 血管生成素样3表达的调节
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CN103189056A (zh) 2010-07-20 2013-07-03 植物药物公共有限公司 L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗
AU2013337308B2 (en) 2012-11-05 2018-06-21 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
ES2623368T3 (es) 2013-03-14 2017-07-11 Oxford University Innovation Limited Procedimiento de producción de (R)-3-hidroxibutirato de (R)-3-hidroxibutilo
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
DK3558280T3 (da) * 2016-12-21 2023-08-21 Univ Kinderspital Beider Basel Forebyggelse og behandling af migræne
JP7174428B2 (ja) * 2016-12-23 2022-11-17 カトリーケ・ユニフェルシテイト・ルーヴァン 救命救急処置の処置における使用のための３－ヒドロキシブチレートの単独または併用
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
GB2572185A (en) * 2018-03-21 2019-09-25 Chain Biotechnology Ltd Pharmaceutical compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900022854A1 (it) * 2019-12-03 2021-06-03 Dr Schaer S P A Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica
CA3219283A1 (en) 2021-07-17 2023-01-26 Elena GROSS Combination of a ketone body or ketogenic compound with an analgesic or antioxidant
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522422A3 (en) * 1991-07-01 1993-03-17 Mitsubishi Kasei Corporation Process for producing a biodegradable polymer
JP2885261B2 (ja) * 1993-05-17 1999-04-19 三菱瓦斯化学株式会社 ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
CA2283642C (en) * 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
DE69903792T2 (de) * 1998-01-07 2003-08-14 Metabolix Inc Tierfutterzusammensetzungen
AU755348B2 (en) * 1998-07-22 2002-12-12 Cj Cheiljedang Corporation Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers

Also Published As

Publication number Publication date
NZ509739A (en) 2003-10-31
CA2339941A1 (en) 2000-03-23
RU2242227C2 (ru) 2004-12-20
ZA200101260B (en) 2001-08-16
PT1123094E (pt) 2007-06-28
BR9913680A (pt) 2001-06-05
CN1273129C (zh) 2006-09-06
EP1123094B1 (de) 2007-04-11
WO2000015216A1 (en) 2000-03-23
US20040171671A1 (en) 2004-09-02
DE69935799T2 (de) 2007-12-27
CN1316902A (zh) 2001-10-10
EP1123094A4 (de) 2001-10-04
EP1123094A1 (de) 2001-08-16
AU767238B2 (en) 2003-11-06
JP2002524506A (ja) 2002-08-06
KR100805490B1 (ko) 2008-02-20
AU5921299A (en) 2000-04-03
ATE359069T1 (de) 2007-05-15
ES2283133T3 (es) 2007-10-16
KR20010079830A (ko) 2001-08-22
US7351736B2 (en) 2008-04-01
DK1123094T3 (da) 2007-08-20
US20010014696A1 (en) 2001-08-16
HK1035665A1 (en) 2001-12-07

Similar Documents

Publication Publication Date Title
DE69935799D1 (de) Therapeutische zusammenstellungen
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
MX9203543A (es) Medicamento.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
RU94045155A (ru) Способы ингибирования болезни альцгеймера
NL300382I1 (nl) Treatment of pompe's disease
CA2223403A1 (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds
NO20004311L (no) Farmasøytisk sammensetning av topiramat
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
DE69532810D1 (de) Intravenöse alendronatformulierungen
MX9805588A (es) Administracion oral de cantidades efectivas de formas de acido hialuronico.
SE8704248D0 (sv) Medical use
DE3879873T2 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR900015718A (ko) 골관절염 치료제
RU94044454A (ru) Ингибитор аутоимунных заболеваний
MXPA02003495A (es) Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos.
LV11882A (lv) Aminotetralina atvasinajumi sirds un asinsvadu slimibu arstesana
Rail et al. Improvement in nerve condition after plasma exchange for Guillain-Barré syndrome.
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
Dressler et al. Tic of the respiratory muscles: Report of three cases and review of literature
AU1645897A (en) Benzopyran derivative and use of said benzopyran derivative for treating heart disease
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
Káldor et al. Enhancement of methyldopa metabolism with barbiturate
UA10301A (uk) Спосіб лікуваhhя раку шлуhку
DK601788A (da) Anvendelse af antibiotikaene ll-e19020alfa og ll-e19020beta til behandling af visse fjerkraesygdomme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition